FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
PRESSNature
LABELS
Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs)